7-(2-amino-6-fluorophenyl)-1-(4,6-dicyclopropylpyrimidin-5-yl)-4-[(2S,5R)-2,5-dimethyl-4-prop-2-enoylpiperazin-1-yl]-6-fluoropyrido[2,3-d]pyrimidin-2-one | 2559761-14-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 7-(2-amino-6-fluorophenyl)-1-(4,6-dicyclopropylpyrimidin-5-yl)-4-[(2S,5R)-2,5-dimethyl-4-prop-2-enoylpiperazin-1-yl]-6-fluoropyrido[2,3-d]pyrimidin-2-one
• 英文别名: Garsorasib
• CAS: 2559761-14-5
• 化学式: C₃₂H₃₂F₂N₈O₂
• 分子量: 598.655
• InChiKey: DKFRWZJCNPETGI-SJORKVTESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  44
• 可旋转键数：
  6
• 环数：
  7.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  121
• 氢给体数：
  1
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  4,6-dicyclopropylpyrimidin-5-amine 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 potassium acetate 、 双(三甲基硅烷基)氨基钾 、 N,N-二异丙基乙胺 、 三氯氧磷 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 水 、 1,2-二氯乙烷 、 乙腈 为溶剂， 反应 9.75h， 生成 7-(2-amino-6-fluorophenyl)-1-(4,6-dicyclopropylpyrimidin-5-yl)-4-[(2S,5R)-2,5-dimethyl-4-prop-2-enoylpiperazin-1-yl]-6-fluoropyrido[2,3-d]pyrimidin-2-one
  参考文献：
  名称：

  [EN] HETEROCYCLIC COMPOUNDS, PREPARATION METHODS AND USES THEREOF
  [FR] COMPOSÉS HÉTÉROCYCLIQUES, LEURS PROCÉDÉS DE PRÉPARATION ET LEURS UTILISATIONS

  摘要：

  本文提供了新颖的化合物，例如具有化学式(I)或化学式(II)的化合物，或其药用可接受的盐。本文还提供了制备这些化合物的方法以及使用这些化合物的方法，例如，在细胞中抑制KRAS G12C，和/或用于治疗各种癌症，如胰腺癌、子宫内膜癌、结肠癌或肺癌（例如非小细胞肺癌）。

  公开号：

  WO2020233592A1

文献信息

• [EN] SOLID DISPERSIONS<br/>[FR] DISPERSIONS SOLIDES
  申请人：INVENTISBIO CO LTD

  公开号：WO2022188849A1

  公开（公告）日：2022-09-15

  Provided herein are solid dispersions and pharmaceutical compositions of Compound 1. Also provided are methods of treating a disease or disorder such as a cancer or infectious disease that comprises administering to a subject in need thereof the solid dispersions or compositions described herein.

  本文提供了化合物1的固体分散和药物组合物。还提供了治疗癌症或传染性疾病等疾病或障碍的方法，该方法包括向需要的受试者施用本文所描述的固体分散或组合物。
• Heterocyclic compounds, preparation and methods and uses thereof
  申请人：InventisBio Co., Ltd.

  公开号：US11091481B2

  公开（公告）日：2021-08-17

  Provided herein are novel compounds, for example, compounds having a Formula (I) or Formula (II), or a pharmaceutically acceptable salt thereof. Also provided herein are methods of preparing the compounds and methods of using the compounds, for example, in inhibiting KRAS G12C in a cell, and/or in treating various cancer such as pancreatic cancer, endometrial cancer, colorectal cancer, or lung cancer (e.g., non-small cell lung cancer).

  本文提供了新型化合物，例如具有式（I）或式（II）的化合物或其药学上可接受的盐。本文还提供了制备这些化合物的方法和使用这些化合物的方法，例如抑制细胞中的 KRAS G12C，和/或治疗各种癌症，如胰腺癌、子宫内膜癌、结直肠癌或肺癌（如非小细胞肺癌）。
• Heterocyclic compounds, preparation methods and uses thereof
  申请人：InventisBio Co., Ltd.

  公开号：US11241437B2

  公开（公告）日：2022-02-08

  Provided herein are compounds, crystalline forms, and pharmaceutical compositions of Compound 1 and/or Compound 2. Also provided are methods of treating a disease or disorder such as a cancer or infectious disease that comprises administering to a subject in need thereof one or more of the compounds or compositions of the present disclosure.

  本文提供了化合物 1 和/或化合物 2 的化合物、结晶形式和药物组合物。还提供了治疗癌症或传染病等疾病或紊乱的方法，包括向有需要的受试者施用一种或多种本公开的化合物或组合物。
• HETEROCYCLIC COMPOUNDS, PREPARATION AND METHODS AND USES THEREOF
  申请人：InventisBio Co., Ltd.

  公开号：US20210198255A1

  公开（公告）日：2021-07-01

  Provided herein are novel compounds, for example, compounds having a Formula (I) or Formula (II), or a pharmaceutically acceptable salt thereof. Also provided herein are methods of preparing the compounds and methods of using the compounds, for example, in inhibiting KRAS G12C in a cell, and/or in treating various cancer such as pancreatic cancer, endometrial cancer, colorectal cancer, or lung cancer (e.g., non-small cell lung cancer).
• HETEROCYCLIC COMPOUNDS, PREPARATION METHODS AND USES THEREOF
  申请人：InventisBio Co., Ltd.

  公开号：US20210355125A1

  公开（公告）日：2021-11-18

  Provided herein are novel compounds, for example, compounds having a Formula (I) or Formula (II), or a pharmaceutically acceptable salt thereof. Also provided herein are methods of preparing the compounds and methods of using the compounds, for example, in inhibiting KRAS G12C in a cell, and/or in treating various cancer such as pancreatic cancer, endometrial cancer, colorectal cancer, or lung cancer (e.g., non-small cell lung cancer).